| Document |
Document Title |
|
WO/1996/038559A1 |
The invention relates to mutant chemokines and pharmaceutical compositions thereof, wherein the mutant inhibits the corresponding endogenous chemokine from binding or activating a responsive receptor. The claimed mutant chemokines can be...
|
|
WO/1996/037500A1 |
The description relates to quinoxaline dione derivatives of the formula (I) and their use in medicaments.
|
|
WO/1996/033678A1 |
A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pKa of about 8.0 or greater, an ef...
|
|
WO/1996/032109A2 |
Levobupivacaine is useful as an anaesthetic in pregnant women. For this or other purposes, it may be formulated in a relatively high concentration, e.g. above 0.75 %.
|
|
WO/1996/030339A1 |
A compound of formula (I) and its pharmaceutically acceptable salt, wherein A is hydrogen, hydroxy or OY, wherein Y is a hydroxy protecting group; Ar is phenyl optionally substituted with one or more substituents selected from halo, hydr...
|
|
WO/1996/029052A1 |
Non-volatile general anesthetics are advantageously provided to patients in aerosolized form using a metered dose inhaler. The anesthetics are highly lipophilic in character and are rapidly absorbed through the nasal, oral, and lung muco...
|
|
WO/1996/029064A1 |
Pharmaceutical compositions containing 2,6-diisopropylphenol (propofol) are described for use as anaesthetics. A method for their preparation is described, as their use in producing anaesthesia including induction and maintenance of gene...
|
|
WO/1996/029066A1 |
Prilocaine base, in liquid and micro rod crystal form, can be solubilized within hydrofluorocarbon propellants to produce a stable, oily liquid. The prilocaine base can be used to solubilize additional medicaments within hydrofluorocarbo...
|
|
WO/1996/016076A1 |
Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
|
WO/1996/008241A1 |
A high pressure pre-mixed analgesic anaesthetic gas composition comprising a life supporting gas and a volatile analgesic anaesthetic mixture; characterised in that the mixture comprises a first and a second anaesthetic analgesic, said f...
|
|
WO/1996/001629A1 |
A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.
|
|
WO/1996/000047A1 |
A non-abusable, non-inflammatory, biocompatible, non-biodegradable, subcutaneous, polymeric implant for the prolonged, controlled release of hydromorphone with near zero-order kinetics is described. Methods of alleviating cancer pain and...
|
|
WO/1995/032973A1 |
A process is described for the synthesis of nalbuphine. The process results in a product having very low levels of the undesirable 'beta'-epimer. The process is a five-step synthesis that begins with a compound such as an N,03-bis(alkoxy...
|
|
WO/1995/024903A1 |
This invention relates to the use of amino hydrogenated quinazoline compounds and derivatives thereof, such as tetrodotoxin, for abstaining from drug dependence in human. Such compounds are administered by subcutaneous, intramuscular or ...
|
|
WO/1995/022965A2 |
The present invention relates to the management of chronic pain without requiring administration of narcotics, and to self-management of pain on an outpatient basis. The invention further relates to facilitating detoxification and treatm...
|
|
WO/1995/021821A1 |
New compounds of formula (A), a process for their preparation and their use in the manufacture of pharmaceutical preparations. The new compounds have both local anaesthetic and analgesic effect.
|
|
WO/1995/019968A1 |
Compounds of formula (I) which are 'alpha'2A selective agonists and methods of selectively stimulating 'alpha'2A adrenoceptors for therapeutic effect in a mammal by administration of compounds of formula (I) wherein R1 is alkyl or alkeny...
|
|
WO/1995/018793A1 |
The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof (I) in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compos...
|
|
WO/1995/017894A1 |
Use of a compound of formula (I) or its pharmaceutically acceptable salts, wherein R1 is a fluorine, chlorine or bromium atom, or a nitro group or -O-(C1-C6)-alkyl; R2 is a fluorine, chlorine or bromine atom, or a nitro group or -O-(C1-C...
|
|
WO/1995/014478A1 |
A purine compound, which has a desired and an undesired effect when a dosage sufficient to induce the desired effect is administered to a mammal, is combined with a counteracting agent, wherein the counteracting agent can reduce the unde...
|
|
WO/1995/012576A1 |
The new cyclopropyl derivatives have formula (I) wherein R is cyclopropyl or methylcyclopropyl. The preparation process comprises reacting 2,6-dibromohexanoyl chloride with 2,6-dimethylanyline in the presence of a base at 0�-25 �C to...
|
|
WO/1995/011680A1 |
Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one o...
|
|
WO/1995/011021A1 |
A pharmaceutical composition, useful for treating animals of the mammalian species, including humans, to treat diseases and conditions which normally respond to treatment with alpha2 adrenergic agents, contains as its active alpha2 adren...
|
|
WO/1995/010280A1 |
A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having formula (I), and pharmaceuticall...
|
|
WO/1995/000522A1 |
Compounds have formula (I), in which R1, R2 may represent independently from each other hydrogen, lower alkyl, cycloalkyl or arylmethyl; R3, R4 may represent independently from each other hydrogen, lower alkyl, or one of the groups -OR6 ...
|
|
WO/1995/000148A1 |
Use of a pharmaceutically acceptable salt of ropivacaine for the manufacture of a pharmaceutical preparation with sensoric block and minimal motor blockade.
|
|
WO/1994/023727A1 |
An analgesic anaesthetic composition comprising up to 50 % v\v nitrous oxide, the balance being oxygen and another respirable gas; characterised by the addition of an analgesically effective amount of an ether-based analgesic anaesthetic...
|
|
WO/1994/022422A1 |
The composition of the present invention combines the local anaesthetic lidocaine in free base form and the non-CFC aerosol propellant HFC-134a (1,1,1,2-tetrafluoroethane; CF3CH2F) or HFC-227 (1,1,1,2,3,3,3-Heptafluoropropane; CF3CHFCF3)...
|
|
WO/1994/017016A1 |
In one aspect the invention relates to the preparation of deuterated sevoflurane and its use as an inhalation anesthetic. In a further aspect the invention relates to the minimization of degradation of sevoflurane to F2-C = C(CF3)OCH2F (...
|
|
WO/1993/019056A1 |
This invention provides aminocyclohexylamides for use within methods of blocking sodium channels in cardiac or neuronal tissue and for use in the manufacture of medicaments to block sodium channels in cardiac or neuronal tissue. This inv...
|
|
WO/1993/007856A1 |
A skin care composition in the form of a low pH aqueous gel. The compositions provide improved skinfeel and residue characteristics together with excellent moisturizing, emolliency, rub-in and absorption characteristics. The gel comprise...
|
|
WO/1993/000932A1 |
A method of controlling the duration of local anesthesia and a reagent system or kit for inducing and limiting the duration of local anesthesia is described.
|
|
WO/1992/019261A1 |
A method of inducing a temporary substantial paralysis of an area of interest in a patient undergoing a medical procedure is provided. The method involves administering a therapeutically effective amount of vasoactive intestinal peptide ...
|
|
WO/1992/019581A1 |
The invention relates to water soluble derivatives of 4-hydroxy butyric acid (GHB) of the formulae (I) and (II), wherein R1, R2 and R3 represent H, CH�3?, C�2?H�5?, CH�2?OH-CH�2? or CH�2?OH-CHOH-CH�2? residues, or form with...
|
|
WO/1992/016202A1 |
A percutaneous anaesthetic delivery system comprises a skin conformable backing layer, an amethocaine-bearing material and a layer having little or no tendency to absorb amethocaine intermediate the backing layer and the layer of amethoc...
|
|
WO/1992/013533A1 |
A storage stable composition for topical anaesthesia comprises amethocaine and a pharmaceutically acceptable salt present in amount of from 1 to 30 % by weight of the composition, which composition has a pH of not less than pH 7.0.
|
|
WO/1992/012128A1 |
This invention relates to (amidomethyl)nitrogen heterocyclic and pyrrolidine compounds of formula (I), pharmaceutical compositions containing them, methods of using such compounds and processes for making such compounds.
|
|
WO/1992/008684A1 |
Disclosed are mixtures of homologous lauryl polyglycol ethers of the formula: C¿12?H¿25?O(CH¿2?-CH¿2?O)¿x?-H in which C¿12?H¿25? is a straight-chain primary alkyl group and x has a mean value of 5 to 7. The homologous range of the...
|
|
WO/1991/016903A2 |
A method of inducing anesthesia, hypothermia, and analgesia, and a method of treating stress and hypothermia by administering an amount of adenosine or adenine nucleotides to a patient in need of anesthesia or analgesia, or requiring ind...
|
|
WO/1991/014455A1 |
The present invention relates to an aqueous suspension preparation for injection and to a method for producing the same and further relates to the use of said preparation for producing pain relief. The invention particularly relates to a...
|
|
WO/1990/005542A1 |
The invention relates to the use of a chemical local anaesthetic agent for production of a medicament for prophylactic or therapeutic inhibition of increased permeability in the blood vessels, which contributes to preventing increased pl...
|
|
WO/1990/002726A1 |
Compounds of the general formula: A-B, where A is a carboxylic acid group having a carbon chain of 3-10 carbon atoms and preferably being branched, and which includes one or more oxo groups, and B is hydrogen, a pharmaceutically acceptab...
|
|
WO/1985/002850A1 |
New peptide hormone (cardiodilatine) and production process. Its amino acid sequence is as follows: Asn-Pro-Val-Tyr-Gly-Ser-Val-Ser-Asn-Ala-Asp-Leu-Met-Asp-Phe-
Lys-Asn-Leu-Leu-Asp-His-leu-Glu-Asp-Lys-Met-Pro-Leu-Glu-Asp-
GLu-Ala-Met-Pro...
|
|
WO/1985/000599A1 |
The local anesthetic, L-N-n-propylpipecolic acid-2,6-xylidide of formula (I). This compound is prepared by chlorinating L-pipecolic acid to yield the acid chloride, namely L-pipecolic acid chloride. The acid chloride is then reacted with...
|
|
JP7460264B2 |
Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treati...
|
|
JP7455852B2 |
Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
|
|
JP2024513303A |
The present invention provides an oral thin film comprising at least one matrix polymer and at least one pharmaceutically active ingredient, wherein the at least one pharmaceutically active ingredient is an acid or a base. The oral thin ...
|
|
JP2024513147A |
The present invention relates to calcium hydroxyapatite particles that are sintered at a certain temperature range and not processed at temperatures above this range. Furthermore, the invention relates to injectable compositions containi...
|
|
JP2024512704A |
Emulsions and uses of emulsions for pain relief comprising a local anesthetic, lecithin, an oil and an aqueous phase, wherein the local anesthetic is non-covalently bound to the emulsion oil droplets and the emulsion is physically and ch...
|
|
JP2024512494A |
The present invention relates to suture materials comprising at least one polymer and at least one eutectic mixture. The polymer can be a biocompatible polymer such as polycaprolactone or PLGA. The eutectic mixture may include maleic aci...
|
